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-Secretase inhibitors have been considered promising drug candidates against 
Alzheimer’s disease (AD) due to their ability to reduce amyloid- (A) production. 
However, clinical trials have been halted due to lack of clinical efficacy and/or side 
effects. Recent in vitro studies suggest that low doses of -secretase inhibitors may 
instead increase A production. Using a stem cell-derived human model of cortical 
neurons and low doses of the -secretase inhibitor DAPT, the effects on a variety of 
A peptides were studied using mass spectrometry.  One major focus was to develop 
a novel method for specific detection of oligomeric A (oA), and this was used to 
study the effects of low-dose -secretase inhibitor treatment on intracellular oA 
accumulation.  Low-dose treatment (2 and 20 nM) with DAPT increased the 
production of several A peptides. Furthermore, using the novel method for oA 
detection, we found that 2 nM DAPT treatment of cortical neurons resulted in 
increased oA accumulation. Thus, low dose-treatment with DAPT causes both 
increased production of long, aggregation-prone A peptides, and accumulation of 
intracellular A oligomers, both believed to contribute to AD pathology.   
 









Plaques, composed of the aggregation-prone peptide amyloid- (A), are key 
pathological hallmarks of Alzheimer’s disease (AD). Ever since the amyloid cascade 
hypothesis was proposed in 1991 (Hardy & Allsop, 1991), much research on AD 
pathogenesis has focused on the mechanisms behind A generation and degradation. 
In line with this, several drug candidates have been developed, aiming at reducing A 
production by inhibiting or modulating the key enzymes involved in the production of 
A. A is generated by sequential cleavage of the amyloid precursor protein (APP) 
by -secretase followed by -secretase (Blennow et al, 2006), and therefore both - 
and -secretase inhibitors have been proposed as possible treatments for AD.  
The first -secretase inhibitor (GSI) showing in vivo reduction of Aβ in the 
brain was N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester 
(DAPT) (Dovey et al, 2001), although failing to reach clinical testing. It has since 
then been widely used in vitro to study different aspects of APP cleavage and Aβ 
generation. Other GSIs, such as semagacestat  (also called LY-450139) and 
avagacestat, have been developed thereafter, but the phase III trial with semagacestat 
and the phase II trial with avagacestat were struck by side effects (Coric et al, 2012; 
Imbimbo et al, 2011), and even leading to deteriorating cognition (Doody et al, 2013). 
-Secretase has many other substrates besides APP, including NOTCH, a protein 
important during neuronal development and maintenance (Imayoshi et al, 2010). The 
inhibition of NOTCH cleavage may therefore be one cause for the severe side effects 
of GSIs (Henley et al, 2014), as could accumulation of toxic APP cleavage products 
(Mitani et al, 2012). In addition, upon treatment with GSIs, it has been reported that 
the initial decrease in A levels in blood is followed by an increase in A levels, as 
the drug concentration in plasma decreases (De Strooper, 2014). Interestingly, both in 
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vivo and in vitro studies have shown that low doses of both semagacestat and DAPT 
increase A levels, instead of decreasing them (Barnwell et al, 2014; Lanz et al, 
2006).  
Because the A peptide is hydrophobic, accumulation causes it to aggregate 
into soluble oligomers and further on into insoluble fibrils, the constituent of A 
plaques (Blennow et al, 2006). It has been reported that deposits of extracellular A 
do not correlate with cognitive symptoms and that A plaques may be present several 
years before symptom onset in AD (Perrin et al, 2009). Additionally, compact 
plaques consisting of A fibrils are found in non-demented individuals (Guillozet et 
al, 2003), and it is now believed that the soluble oligomeric A (oA) is the most 
toxic species (Benilova et al, 2012). Soluble forms of synthetic as well as naturally 
produced oA are toxic to cells in vitro and in vivo (Hoshi et al, 2003; Lambert et al, 
1998; Takuma et al, 2004), and have the ability to disrupt cognitive function (Cleary 
et al, 2005). Due to the importance of oA in AD pathogenesis, there is a need for 
reliable methods to detect oA. Previously, oligomer-specific antibodies such as the 
polyclonal anti-oligomer antibody A11, have been developed. However, this antibody 
also detects oligomers from other proteins such as insulin, prion protein and lysozyme 
(Kayed et al, 2003). Different dyes, such as congo red and thioflavin S/T stain A 
fibrils and protofibrils, but do not recognize smaller oligomers of A (Walsh et al, 
1999). In addition, small probes (luminescent conjugated oligothiophenes; LCOs) 
have been shown to bind to aggregated A in diffuse plaques (Nilsson et al, 2006), 
and seem to detect smaller A aggregates than traditional dyes, but are not specific 
for A aggregates. It is therefore of importance to develop new sensitive and specific 
methods for detection of oA. Recently, a method based on the proximity ligation 
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assay (PLA) for detection of -synuclein oligomers was described (Roberts et al, 
2015). Here, we used the same approach to develop an assay for detection and 
quantification of intracellular oA. This oA method, along with immunochemical 
quantification of Ax-38, Ax-40, and Ax-42 and immunoprecipitation-mass 
spectrometry (IP-MS) analysis of secreted A peptides, was used to examine the 
effects of low-dose -secretase inhibition on production of a variety of A peptides 
and the potential accumulation of intracellular oA in a previously established human 
neuronal model (Shi et al, 2012) that produces all relevant A peptides (Bergström et 
al, 2016).  
 
Results 
Low-dose -secretase inhibition increases secretion of A42 without affecting 
intracellular C-terminal fragment of APP 
To test the hypothesis that low-dose -secretase inhibition increases 
production of long A peptides, human induced pluripotent stem cell (iPSC)-derived 
cortical neurons were treated with 2, 20 or 200 nM DAPT for 48 hours. Thereafter, 
cell culture media were collected and analysed for secreted Ax-38, Ax-40, and 
Ax-42. Treatment with 2 or 20 nM DAPT tended to increase the secreted levels of 
Ax-38 (Figure 1A) and Ax-40 (Figure 1B) compared with control, although the 
difference did not reach statistical significance, while secretion of Ax-42 (Figure 
1C) was significantly increased upon treatment with 2 and 20 nM DAPT. Treatment 
with 200 nM DAPT significantly decreased the secretion of all three peptides 
compared with control. This shows that low-dose treatment with the -secretase 
inhibitor DAPT increases the secretion of all A peptides quantified, although only 
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reaching statistical significance for Ax-42. A higher concentration (200 nM) 
decreased the production of all three A peptides.  
In addition, the effect of DAPT treatment on the Ax-42/38 and Ax-42/40 
ratios was also investigated. Treatment with 20 nM DAPT increased the A42/38 
ratio, which was further increased upon treatment with 200 nM DAPT (Figure 1D). 
Treatment with 200 nM DAPT also significantly increased the Ax-42/40 ratio 
(Figure 1E). To investigate if the increased secretion of A was accompanied by a 
change in the APP C-terminal fragment (the substrate for -secretase), western blot 
analysis was performed on cell lysates. While treatment with 2 or 20 nM DAPT did 
not change the levels of intracellular C-terminal fragments compared with control, 
they were significantly increased upon 200 nM DAPT treatment (Figure 1F). 
 
Low-dose -secretase inhibition affects different A peptides differently and dose-
dependently 
A more detailed investigation of the effects of low-dose GSI treatment on A 
peptide secretion, was performed by analysing conditioned cell culture media using 
immunoprecipitation (IP) followed by mass spectrometry (MS). The relative levels of 
all secreted peptides were calculated by dividing the peak area of each peptide by the 
total peak areas for all peptides detected. Relative secretion levels of the short A1-16 
(Figure 2A) was not affected by 2 or 20 nM DAPT but was, as expected (Portelius et 
al, 2009), increased when cells were exposed to 200 nM DAPT. This suggests that -
secretase is not involved in the production of A1-16, but rather that the decrease in 
-secretase activity allows for an increase of other secretases. In contrast, A1-17 was 
significantly decreased upon treatment with 200 nM DAPT, with a trend towards 
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decrease upon 20 nM DAPT treatment (Figure 2B). A similar tendency was seen for 
A1-19 (Figure 2C), although not reaching statistical significance, indicating that 
production of these two peptides can be -secretase-dependent. Interestingly, A1-20 
had a similar secretion pattern as A1-16, with a tendency to increase dose-
dependently upon DAPT treatment (Figure 2D). Secretion of A1-33 was not 
significantly decreased by low doses of DAPT, but completely abolished upon 
treatment with 200 nM (Figure 2E). A direct dose-dependent decrease in secretion of 
A1-34 (Figure 2F) was seen upon treatment with increasing doses of DAPT. The 
longer peptides A5-40 (Figure 2G), A1-37 (Figure 2H), A1-38 (Figure 2I), A1-
39 (Figure 2J), A1-40 (Figure 2K) and A1-42 (Figure 2L) all follow the same 
trend, however statistically non-significant, towards increased secretion upon 
treatment with 2 and 20 nM DAPT, which was strongly reduced upon treatment with 
200 nM DAPT. This suggests that one set of short A peptides, especially A1-16, 
increases upon DAPT treatment. Other shorter peptides tend to decrease already at 
low doses of DAPT, being significant for A1-34, whereas longer A peptides, 
starting with A1-37, only decrease with high doses. It has earlier been shown that 
A1-34 is the A peptide that is most sensitive to -secretase inhibition (Portelius et 
al, 2010). Indeed, we found a dose-dependent decrease in relative A1-34 secretion, 
starting already at 2 nM DAPT. In addition, -secreatse dependent cleavage of Notch 
results in expression of a number of Notch response genes, including the HES-genes 
(Kageyama et al, 2008). We measured the expression of the neuronal-relevant HES 
gene HES1 upon treatment with 2, 20 and 200 nM DAPT and found that all three 
doses decreased HES1 expression to a similar level, compared to control 
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(Supplementary figure 1). Taken together, this shows that as low concentration as 2 
nM DAPT is enough to reduce -secretase activity.  
 
A novel method to detect oligomeric A 
As low doses of the -secretase inhibitor DAPT increase the production/secretion of 
longer, more aggregation-prone A peptides and decrease, or do not affect, the 
production of shorter, we were interested in investigating the effects of low-dose -
secretase inhibition on intracellular oA accumulation. A novel method for oA 
detection was developed using proximity ligation assay (PLA; Duolink), by 
conjugating PLUS and MINUS Duolink probes to the N-terminal specific A 
antibody 82E1 (Horikoshi et al, 2004). The method was optimized on oA1-42 
(Supplementary figure 1A) fed to SH-SY5Y cells, as previously described (Domert et 
al, 2014). Using immunocytochemistry, it was evident that the 82E1 antibody was 
able to detect intracellular A1-42 (Supplementary figure 1B, first panel), but as 
predicted, the control peptide A42-1 was not detected (Supplementary figure 1B, 
second panel). SH-SY5Y cells were thereafter fed with increasing concentrations of 
oA1-42 (125, 250 and 500 nM) and re-seeded to contain only intracellular oAβ. 
Using PLUS and MINUS probe-conjugated 82E1 antibody to visualize the oAβ, we 
found that intracellular A oligomers could be detected in cells fed with 125 nM oA 
(Figure 3A, first panel). Increasing concentrations of oA increased the number of 
positive Duolink spots dose-dependently (Figure 3A, second and third panels). 
Staining of the reverse peptide A42-1 only resulted in very few positive Duolink 
spots (Figure 3A, last panel), regarded as background staining. 
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Quantification of the number of Duolink spots (one spot representing one 
oligomeric A assembly) was performed using the Volocity software, and calculated 
as number of Duolink spots per cell. Already at 125 nM oA, the number of spots per 
cell increased significantly compared with the control peptide A42-1 (Figure 3B), 
and there were significant differences between all concentrations tested. This shows 
that the Duolink method successfully detects intracellular oA at as low 
concentrations as 125 nM.  
To test that the Duolink method does not detect monomeric A, SH-SY5Y 
cells were also fed with the non-oligomerizing peptide A1-15. However, this peptide 
was not efficiently taken up by the SH-SY5Y cells, and could not be detected by 
immunocytochemistry using the 82E1 antibody (Supplementary figure 1B, third 
panel). Instead, pure protein solutions of oA1-42 or A1-15 were added to glass 
slides and let to dry. Samples were incubated with Duolink probes and reagents, 
followed by immunocytochemistry to detect both oligomeric and monomeric A. 
While monomeric A1-15 was detected with immunocytochemistry, using the 82E1 
antibody, the Duolink method did not give a positive signal (Supplementary figure 
1C, upper panels). On the contrary, oA1-42 was successfully detected with both 
immunocytochemistry and Duolink (Supplementary figure 1C, lower panels). In 
conclusion, this shows that oligomeric A can be specifically and sensitively detected 
using the Duolink method. 
 
Low-dose -secretase inhibition causes intracellular accumulation of oligomeric A 
in cortical neurons 
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iPSC-derived neurons were treated with low concentrations of DAPT and thereafter 
analysed for oA using the Duolink method described above. A few Duolink spots 
were seen in control cells (Figure 4A, first panel), whereas an increased number of 
Duolink spots were seen in cells treated with 2 nM of DAPT (Figure 4A, second 
panel). Treatment with 20 or 200 nM DAPT did not seem to increase the number of 
Duolink spots compared with control (Figure 4A, third and fourth panel). Analysis of 
the number of Duolink spots per neuron showed that treatment with 2 nM DAPT 
almost doubled the number of Duolink spots per cell compared with control. There 
was no difference between control cells and cells treated with 20 or 200 nM DAPT 
(Figure 4B). In addition, we measured the levels of secreted oA, and found that 
iPSC-derived cortical neurons secreted measurable levels of oA (around 60-100 fM), 
but that DAPT treatment did not affect secretion (Supplementary figure 3). This 
suggests that treatment of neurons with low doses of the -secretase inhibitor DAPT 
not only results in increased secretion of long, aggregation prone A peptides, but 
also causes an intracellular accumulation of oligomeric A.  
 
Discussion 
The failed clinical trials based on -secretase inhibition have led to an 
abandonment of these drugs in AD drug development. It is, however, still important 
to fully investigate the effect of partial γ-secretase inhibition, as is seen when blood 
and brain concentrations of -secretase inhibitors fluctuate due to once-a-day 
administration (De Strooper, 2014). In this study, we performed a detailed 
investigation of the effects of partial -secretase inhibition on secreted A peptides, as 
well as on intracellular oA accumulation, using a human iPSC-derived neuronal cell 
model.  
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We found that low-dose -secretase inhibition in human iPSC-derived cortical 
neurons tended to increase the relative levels of longer A peptides (including all 
peptides ending at amino acid 37 through 42), and decreased the relative levels of 
shorter non-aggregation prone peptides such as A1-34. Furthermore, treatment with 
2 nM DAPT increased the number of intracellular oA aggregates, which are 
suggested to function as seeds for further A aggregation and plaque formation 
(Gouras et al, 2010).  
Quantitative analysis of Ax-38/40/42 indicated an increase in secretion of 
Ax-42 when cells were treated with 2 and 20 nM DAPT, whereas Ax-38 and Ax- 
40 did not increase significantly. The ratio of A42 over A38 was significantly 
increased upon treatment with 20 nM DAPT, whereas the A42/40 ratio was 
unchanged. Interestingly, although the highest dose of DAPT tested decreased the 
secretion of A38/40/42, the ratio of both A42/38 and A42/40 increased, 
suggesting that the effect of -secretase inhibition is greater on shorter A peptides 
also at higher concentrations. In support of this, it was shown that semagacestat more 
effectively inhibited production of A1-40 than A1-42 in a human trial (Lanz et al, 
2006). Taken together, these results suggest that GSIs may tilt the ratio towards 
longer, more aggregation-prone A peptides.  
To further investigate the effects of low-dose DAPT treatment on neurons, we 
also performed IP-MS, enabling simultaneous detection of a variety of secreted A 
peptides (Portelius et al, 2007). It showed three different types of A peptide 
secretion patterns upon DAPT treatment. The shortest peptide, A1-16, was not 
affected by 2 or 20 nM DAPT, but increased dramatically upon 200 nM DAPT 
treatment, further supporting that generation of this peptide is -secretase-independent 
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(Portelius et al, 2010). A similar trend was seen for the A1-20 peptide, suggesting 
that generation of neither peptide involves -secretase cleavage. We have earlier 
shown that A1-16 is produced by concerted α/β-secretase cleavage (Portelius et al, 
2011), and a similar mechanism could be true for A1-20. However, both a second -
secretase (BACE2) and insulin-degrading enzyme have been suggested to cleave A 
at position 20 (Andreasson et al, 2007). Reduced -secretase activity could leave more 
APP C-terminal fragment available for these alternative, normally less common, 
cleavage pathways. 
A dose-dependent decrease in secretion was seen for A1-34 for all doses 
tested, and a similar trend was observed for A1-17 and 1-19 upon treatment with 20 
and 200 nM DAPT. This suggests that cleavage of these peptides is very sensitive to 
-secretase inhibition (Portelius et al, 2010). All is not known regarding the 
generation of these peptides, but it has been suggested that A1-34 is generated by a 
second BACE1 cleavage, requiring a preceding -secretase cleavage upstream 
(Portelius et al, 2014), which our data supports. 
A third group of A peptides, starting at A5-40 and including all longer 
peptides up until A1-42 all had a general tendency to increase upon treatment with 2 
and 20 nM DAPT. The relative levels of all these peptides were significantly 
decreased upon treatment with 200 nM DAPT, supporting the results obtained by the 
quantification of Ax-38/40/42.  
We hypothesised that partial inhibition of -secretase would result in increased 
levels of longer A peptides, as the step-wise removal of amino acids from the C-
terminal end of A would be hampered, based on the finding that cleavage of APP by 
-secretase starts at the ζ- and ε-sites  (resulting in 46 or 49 amino acid long peptides) 
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(Zhang et al, 2012). Thereafter amino acids are removed step by step by -secretase, 
resulting in A peptides varying from 38-43 amino acids. -Secretase inhibition of 
CHO cells overexpressing the C-terminal fragment of APP resulted in increased 
levels of A43 and A46, whereas A40 decreased (Yagishita et al, 2006). Although 
we found a relative increase in all A peptides from 37 amino acids of length, the 
increased A42/38 ratio at 20 nM, and both A42/38 and A42/40 at 200 nM DAPT 
treatment could further support this idea.  
As oA is thought to play an important role in AD pathogenesis (Benilova et 
al, 2012), there is a need for specific and sensitive methods for oA detection in cells 
and tissue. Several methods have been developed for detection of oligomeric and 
fibrillar A, although most being conformational specific and lacking specificity for 
A (Kayed et al, 2003), or only recognizing larger A aggregates (Walsh et al, 1999). 
We therefore developed a novel method, based on proximity ligation, utilizing the N-
terminal specificity of the 82E1 antibody, together with the epitope blocking upon 
binding (Horikoshi et al, 2004). Therefore, signals detected were specific for binding 
of two 82E1 antibodies, conjugated to one PLUS and one MINUS probe respectively. 
However, due to the even ratio of PLUS and MINUS probe labelled antibody, there is 
also a chance of two PLUS or two MINUS probes binding in close proximity, 
resulting in detection of only 50% of the possible oligomers. In spite of this, we could 
detect intracellular A from cells fed with a starting concentration of 125 nM A, 
hence being both a specific and sensitive assay for oA detection.  
Intracellular accumulation of A has for long been suggested to play a role in 
AD pathogenesis (Ferreira et al, 2007), with endosomes being a suggested site for A 
production (Small & Gandy, 2006). The acidic environment within the endosomes 
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could favour oligomerization, as could an increased production of longer, 
aggregation-prone A peptides. We therefore went further to investigate the effects of 
low-dose -secretase treatment on intracellular accumulation of oA. Treatment with 
2 nM DAPT resulted in an increased number of Duolink-positive oA spots per cell. 
This effect was abolished already at 20 nM DAPT and no difference was seen 
between 200 nM compared to control. There may be several explanations for this 
specific effect of 2 nM DAPT. It was recently reported that presenilin (PSEN)1 and 
PSEN2, the two variants of the catalytically active subunit of -secretase, cleave A 
in different manners. PSEN1 cleavage also takes place at the plasma membrane, 
resulting in secretion of A, whereas the majority of PSEN2 cleavage takes place 
intracellularly in late endosomes and lysosomes, resulting in intracellular 
accumulation of A (Sannerud et al, 2016). DAPT might, at low doses, 
predominantly inhibit PSEN1 and therefore increase the amounts of APP undergoing 
intracellular A production by PSEN2, hence causing oligomerization. One could 
also speculate that -secretase inhibition generally affects intracellular and membrane-
bound -secretase differently, resulting in this discrepancy. It would of course be 
interesting to repeat these experiments using other GSIs as well. However, as the 
main focus of the study was to develop a method for oA detection and to verify this 
in a neuronal model, this will be the scope for a future study.  
In conclusion, this study shows that exposure of human iPSC-derived neurons 
to low nanomolar concentrations of DAPT induces biochemical changes thought to 
contribute to AD pathology. This includes increased production of long, aggregation-
prone A peptides, together with decreased relative levels of shorter A peptides, as 
well as accumulation of intracellular oA. These effects could contribute to 
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explaining why there were no positive effects upon treatment with -secretase 
inhibitors in clinical trials. 
 
Material and methods 
Induced pluripotent stem cells and neuronal differentiation 
The human iPS cells (iPSCs) were reprogrammed from fibroblasts obtained 
from a healthy donor as described previously (Sposito et al, 2015). The iPSCs were 
differentiated towards cortical neurons according to the protocol by Shi et al. 
(2012), as previously described (Bergstrom et al., 2016). One iPSC line was used in 
the experiments, and the experiments were performed using three separate 
differentiations.  
 
DAPT treatment and sample collection 
Neurons differentiated for 75-90 days were treated with 2, 20 or 200 nM N-
[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT; 
Sigma-Aldrich) in 2 ml of neural maintenance media (NMM) for 48 hours. DMSO 
(Sigma-Aldrich) was used as vehicle control. After 48 hours of DAPT treatment, 
conditioned NMM was collected and centrifuged at 360g for five min before the 
supernatant was transferred to new tubes and stored at -80 °C. For protein analysis, 
cells were washed with Dulbecco's phosphate-buffered saline (DPBS), removed by 
scraping, centrifuged at 400g, and DPBS was removed before storage of cell pellet 
at -80 °C until further analysis. For mRNA analysis, cells were washed once in 
DPBS and thereafter lysed directly in the well by adding 600 l buffer RLT 
supplemented with 4mM dithiothreitol (DTT). Extraction of total RNA and cDNA 




SH-SY5Y cell culturing 
SH-SY5Y neuroblastoma cells (ETCC, Sigma-Aldrich) were cultured in 
DMEM/F12 medium (Life Technologies) supplemented with 10% foetal calf serum 
(FCS) (Sigma-Aldrich) and 1 % Penicillin/Streptomycin (Hyclone, GE Health Care) 
in a humified chamber at 37 °C with 5 % CO2. The cells were differentiated using 
10 μM retinoic acid (RA; Sigma-Aldrich) 5-7 days prior to experiments.  
 
Immunochemical quantification of A peptides 
Media concentrations of Ax-38/40/42 were measured using the MSD Human (6E10) 
Abeta Triplex Assay as described by the manufacturer (Meso Scale Discovery). This 
assay employs C-terminally specific antibodies to capture Ax-38/40/42, 
respectively, and the 6E10 antibody in combination with a SULFO-TAG-labelled 
anti-6E10 to quantify the peptides.  The limit of detection was set to the value of the 
lowest standard point. 
 
Immunoprecipitation and mass spectrometry 
Cell-conditioned media collected throughout differentiation was investigated for Aβ 
peptides using IP-MS as described previously (Portelius et al, 2007) Briefly, 4 g of 
the anti-Aβ antibodies 6E10 and 4G8 (Biolegend) was separately added to 50 l each 
of magnetic Dynabeads M-280 Sheep Anti-Mouse IgG (Invitrogen) and used for IP- 
MS measurements were performed using a Bruker Daltonics UltraFleXtreme matrix-
assisted-laser-desorption/ionization time-of-flight/time-of-flight (MALDI TOF/TOF) 
instrument or a Bruker Daltonics AutoFlex MALDI TOF (Bruker Daltonics). All 
samples were analysed in duplicate. The area of each peak was normalized against the 
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sum of all areas for all A peaks in the spectrum (providing a relative MALDI 
signal).  
Quantitative PCR 
Quantitative PCR was performed using inventoried TaqMan Gene Expression 
Assays with FAM reporter dye in TaqMan Universal PCR Master Mix II with UNG 
(Applied Biosystems) according to protocol, but in a total reaction volume of 25 μl. 
qPCR reactions were carried out on Micro-Amp 96-well optical microtitre plates on 
a  7900HT Fast QPCR System (Applied Biosystems), using standard settings for 
Standard Curve qPCR. TaqMan Gene Expression Assays for the following genes 
were used: Hairy And Enhancer Of Split 1, (Drosophila) (Hes1: Hs00172878_m1); 
ribosomal protein L27 (RPL27: Hs03044961_g1); hypoxanthine 
phosphoribosyltransferase 1 (HPRT1: Hs02800695_m1). 2.5 ng cDNA was used in 
the PCR and all samples were run in duplicates. PCR results were analysed with the 
SDS 2.3 software (Applied Biosystems) and the relative quantity was determined 
using the ΔΔCT method (Livak & Schmittgen, 2001), with the sample with highest 




Cells were lysed using radioimmunoprecipitation assay (RIPA) buffer (20 mM 
Tris-HCl pH 7.5, 150 nM NaCl, 1 nM EDTA, 1 % Triton X-100, 0.5 % sodium 
deoxycholate, 0.1 % SDS) supplemented with protease inhibitor cocktail (Complete 
Mini; Roche), and protein concentration was determined using the Pierce 
bicinchoninic acid (BCA) protein assay (ThermoFisher Scientific). Equal amounts 
of protein were mixed with 4x NuPAGE® LDS sample buffer (Life Technologies) 
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and 50 mM DTT, boiled and then loaded onto a NuPAGE 4-12 % Bis-tris gel. For 
oA, 1 M samples were diluted 1:20, mixed with 4x sample buffer, and loaded 
onto a NuPAGE 4-12 % Bis-tris gel. Proteins were blotted onto a 0.2 m 
nitrocellulose membrane using semi-dry technique. Membranes were blocked using 
5 % milk before incubation with primary antibody over night at 4 °C.  Primary 
antibodies used were anti-C-terminal APP (1:5000; Millipore 171610) and anti--
Amyloid 1-16 (1:1000, clone 6E10; Biolegend). After washing, membranes were 
incubated with a horseradish peroxidase (HRP)-linked Anti-Rabbit IgG or HRP-
linked Anti-Mouse IgG (both 1:2000; Cell Signalling Technology). Proteins were 
visualized using the SuperSignal® West Dura Extended Duration Substrate 
(ThermoFisher Scientific) by the ChemiDoc XRS+ and Image Lab 3.0 software 
(both from Bio-Rad Laboratories). Membranes were stripped using Restore 
stripping buffer (ThermoFisher Scientific) and re-probed using HRP-conjugated 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (1:20000; Novus 
biological). Densitometry quantification was performed using ImageJ (NIH).  
 
Aβ oligomerization 
Aβ1-15, 1-42 and 42-1 (all from Bachem) were dissolved to 443 μM in 10 mM 
NaOH, aliquoted and stored at -80 °C until further use. Aβ peptide in 10 mM NaOH 
was mixed with 10 mM HCl and DPBS in a 1:1:2 ratio in protein LoBind tubes 
(Eppendorf) and incubated for 48 hours at 37 °C.  
 
Treatment of cells with A 
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Oligomerized Aβ1-42 and Aβ42-1 were delivered to RA differentiated SH-SY5Y 
cells as previously described (Domert et. al., 2014). Briefly, oAβ was dissolved in 
serum free DMEM/F12 (125, 250 or 500 nM for Aβ1-42, 500 nM for Aβ42-1) and 
cells were incubated with oAβ containing medium for 3 hours. Thereafter, cells were 
washed with PBS, incubated with fresh PBS for 10 min at 37 °C, trypsinized, 
resuspended in DMEM/F12 media and centrifuged at 400g for 5 min. Thereafter, the 




Aβ-fed cells were fixed with 4 % PFA 24 hours after re-seeding. Thereafter, the 
samples were blocked with 5 % donkey serum (Sigma-Aldrich) in 0.3 % Triton-
X100 in TBS for 1 hour at room temperature (RT). The antibody (Anti human A, 
clone 82E1; IBL International) was diluted 1:100 in block buffer and incubated over 
night at 4 °C.  Secondary goat anti mouse Alexa 562-antibody (Life Technologies) 
was diluted 1:400 in block buffer and incubated for 1h at RT. Samples were 
incubated with cell mask (Life Technologies; 1:20000 in TBS) for 10 minutes (for 
visualization of cytosol) and after washing, the samples were mounted onto 
microscope slides using prolong gold antifade mounting media (Life Technologies). 
 
Duolink assay 
Lyophilized anti human A antibody (clone 82E1, IBL international) in PBS 
without BSA or preservatives was reconstituted in H2O to a concentration of 1 
mg/ml. Thereafter one aliquot of the antibody was conjugated to PLUS probe, and 
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one to MINUS probe (all reagents from Sigma-Aldrich if not stated otherwise) 
respectively, according to the manufacturer’s instructions. Samples were fixed in 4 
% PFA in PBS and blocked using 5 % donkey serum in TBS with 0.3 % triton-
X100. Antibody/probe was diluted 1:1000 (for PLUS and MINUS respectively) in 
block buffer containing 1x Duolink assay reagent. Samples were incubated with 
antibody/probe solution over night at 4 °C. The remaining steps were performed 
according to the manufacturer’s instructions using Duolink wash buffers and 
detection reagent red. After polymerase reaction, samples were incubated with 
cell mask (1:20000), and mounted using Duolink mounting media with DAPI and 
sealed with nail polish. Samples were stored at -20 °C until further analysis.  
 
Confocal microscopy and image analysis 
The samples were analysed using a Zeiss LSM700 inverted confocal microscope 
with 40-63x objectives and the ZEN2000 software (Zeiss). From each sample, 10 
images were captured in a randomized manner. Image analysis was performed using 
the Volocity 6.3 Software (PerkinElmer). Duolink spots were detected based on 
fluorescence intensity and size. DAPI-stained nuclei were detected based on 
fluorescence and size. The number of Duolink spots and number of nuclei per image 
was analysed and the number of Duolink spots per nuclei (cell) was calculated.  
 
Statistical analysis 
All results where statistical analysis is performed are presented at means ± S.E.M. 
from three independent repeats. One-way ANOVA was used to compare differences 
between groups, followed by Dunnet’s correction for multiple comparisons. All 
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Figure 1. Low-dose -secretase inhibition increases secretion of A x-42. iPSC-
derived human cortical neurons were treated with various doses (2, 20 and 200 nM) of 
the -secretase inhibitor DAPT for 48 hours and thereafter conditioned media and 
cells were collected. A-C. Immunochemical analysis of secreted Ax-38 (A), Ax-40 
(B) and Ax-42 (C). Treatment with 2 and 20 nM DAPT increases the secretion of 
Ax-42 significantly compared to control, whereas no difference in Ax-38 or Ax-
40 secretion is observed. On the contrary, treatment with 200 nM DAPT decreases the 
secreted levels of Ax-38, Ax-40 and Ax-42. D. The ratio of Ax-42 to Ax-38 is 
significantly increased after treatment with 20nM of DAPT, and further increased 
upon treatment with 200 nM DAPT. E. The ratio of Ax-42 to Ax-40 is significantly 
increased after treatment with 200nM of DAPT. F. Western blot analysis of the C-
terminal fragment of APP (APP C-term) shows that treatment with 2 or 20 nM DAPT 
does not result in increased levels of APP C-terminal fragments, whereas treatment 
with 200 nM of DAPT increases the levels significantly. One representative blot out 
of three is shown. GAPDH was used as loading control, and densitometric analysis 
was used to calculate the ratio of APP C-term to GAPDH. Bars represent mean ± 
SEM, n = 3. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
 
Figure 2. DAPT treatment affects A peptides differentially and dose-
dependently. iPSC-derived human cortical neurons were treated with various doses 
(2, 20 and 200 nM) of the -secretase inhibitor DAPT for 48 hours and thereafter 
conditioned media and cells were collected and analysed using immunoprecipitation 
followed by mass spectrometry (IP-MS). A. Treatment with 2 or 20 nM DAPT does 
not change the relative levels of A1-16, but 200 nM DAPT treatment increases 
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secretion of A1-16 compared with control. B. DAPT treatment tends to decrease the 
relative levels of A1-17 upon 20 nM DAPT treatment, being significantly reduced 
upon 200 nM DAPT compared with control. C. DAPT treatment similarly tends to 
decrease the relative levels of A1-19 upon treatment with 20 or 200 nM DAPT. D. 
Treatment with 20 or 200 nM DAPT tends to increase relative levels of A1-20, 
although not reaching statistical significance. E. Treatment with 200 nM DAPT 
abolishes the levels of A1-33, compared with control. F. DAPT treatment decreases 
the levels of A1-34 dose-dependently. G. Relative levels of A5-40 are not affected 
by 2 or 20 nM DAPT, but decrease upon treatment with 200 nM. H-I. Relative levels 
of A1-37 and 1-38 tend to be slightly increased upon treatment with 2 or 20 nM 
DAPT, but decrease upon treatment with 200 nM compared with control. J. Relative 
levels of A1-39 are not affected by 2 or 20 nM DAPT, and decrease upon treatment 
with 200 nM. K-L. Relative levels of A1-40 and 1-42 tend to slightly increase dose-
dependently upon treatment with 2 or 20 nM DAPT, and decrease upon treatment 
with 200 nM compared with control. Bars represent mean ± SEM, n = 3, * = p < 0.05, 
** = p < 0.01. 
 
Figure 3. Detection of oligomeric A using a proximity ligation based assay.  
SH-SY5Y cells were fed with 125, 250 or 500 nM oligomeric A (oA), or with 
control peptide (A42-1) for three hours, and were thereafter washed and reseeded to 
remove extracellular A peptides. 24 hours after re-seeding, cells were fixed and the 
intracellular oligomeric A was investigated using the proximity ligation assay 
developed by Duolink. A. Representative images of Duolink staining of SY-SY5Y 
cells that have been fed with control peptide (A42-1) or increasing concentrations of 
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oA1-42. Increasing concentration of oA1-42 results in increasing numbers of 
Duolink spots (arrowheads). Duolink spots in red, DAPI-stained nuclei in blue and 
cell mask in green. Scale bar = 25 m.  B. Quantification of Duolink spots per cell 
(DAPI-stained nuclei). The Duolink signal is significantly increased different from 
control in cells fed with 125 nM oA1-42. A significant difference was also seen 
between 125 nM and 250 and 250 nM and 500 nM respectively. Bars represent mean 
± SEM, n = 3. ** = p < 0.01, *** = p < 0.001.  
 
Figure 4. Treatment with low-dose -secretase inhibitor DAPT increases the 
intracellular accumulation of oligomeric A. iPSC-derived neurons were treated 
with various doses (2, 20 and 200 nM) DAPT for 48 hours and thereafter analysed for 
oligomeric A using a Duolink-based method. A. Control cells contain a few positive 
Duolink spots (red), and treatment with 2 nM DAPT increases the number of Duolink 
spots (see arrowheads). Treatment with 20 or 200 nM DAPT does not increase the 
number of Duolink spots compared with control. DAPI-stained nuclei in blue and cell 
mask in green. Scale bar = 15 m. B. Quantification of number of oA Duolink spots 
per cell. Treatment with 2 nM DAPT increases the number of oA spots significantly 
compared to control, and is also significantly higher than cells treated with 20 nM 
DAPT. Treatment with 20 and 200 nM DAPT does not increase the number of oA 
spots compared with control. Bars represent mean ± S.E.M., n=3. * = p < 0.05, ** = p 
< 0.01.  
 
Supplementary figure 1. mRNA expression of Notch response gene HES1 is 
reduced upon low-dose DAPT treatment. Quantitative PCR analysis of Notch 
response gene HES1 in iPSC-derived cortical neurons upon treatment with 2, 20 and 
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200 nM DAPT for 48. A similar reduction in HES1 mRNA is observed for all doses 
of DAPT tested, compared to control. All samples are related to control, n=1. 
 
Supplementary figure 2. A. Western blot of oligomerized A1-42 (oA). Short 
exposure (lane 1) shows the presence of dimers and trimers as well as monomeric A. 
Longer exposure (lane 2) also reveals a trail of positive A staining indicating 
presence of larger A species. B. Immunocytochemistry shows that the n-terminal 
specific A antibody 82E1 detects oA1-42 taken up by SH-SY5Y cells 
(arrowheads). A42-1 is used as negative control. A1-15 is not detected 
intracellularly. Scale bar = 15 m. C. Oligomerized A1-15 and 1-42 was added to 
glass slides and investigated using Duolink (red) followed by immunocytochemistry 
(green). The antibody 82E1 successfully detects A1-15, but this A peptide is not 
detected with the Duolink method. A1-42 is detected both using 
immunocytochemistry (both monomeric and oA) and the Duolink method (oA 
only).  
 
Supplementary figure 3. Secretion of oligomeric A upon low-dose DAPT 
treatment. Detectable levels of oligomeric A were secreted from iPSC-derived 
neurons. No difference in secretion was seen upon treatment with 2, 20 or 200 nM 
DAPT. Bars represent mean +/- SEM, n=2.  
